Cargando…
Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory
Coronavirus disease 2019 (COVID-19) is associated with extreme inflammatory response, disordered hemostasis and high thrombotic risk. A high incidence of thromboembolic events has been reported despite thromboprophylaxis, raising the question of a more effective anticoagulation. First-line hemostasi...
Autores principales: | Hardy, M., Lecompte, T., Douxfils, J., Lessire, S., Dogné, J. M., Chatelain, B., Testa, S., Gouin-Thibault, I., Gruel, Y., Medcalf, R. L., ten Cate, H., Lippi, G., Mullier, F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474970/ https://www.ncbi.nlm.nih.gov/pubmed/32922211 http://dx.doi.org/10.1186/s12959-020-00230-1 |
Ejemplares similares
-
Prothrombotic hemostasis disturbances in patients with severe COVID-19: Individual daily data
por: Hardy, Michaël, et al.
Publicado: (2020) -
Pre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratories
por: Magnette, A., et al.
Publicado: (2016) -
Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study
por: Hardy, Michaël, et al.
Publicado: (2021) -
Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays
por: Douxfils, Jonathan, et al.
Publicado: (2014) -
Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rational for monitoring immunoglobulin G levels
por: Douxfils, Jonathan, et al.
Publicado: (2021)